<DOC>
	<DOCNO>NCT01292304</DOCNO>
	<brief_summary>Open Label Study evaluate safety efficacy tolvaptan treatment ascites liver cirrhosis . Tolvaptan administer combination current ascites management .</brief_summary>
	<brief_title>Tolvaptan Ascites Cirrhotic Patients</brief_title>
	<detailed_description>This open label , 12 week dose escalate pilot study tolvaptan ( initiate 15 mg day increase 30 mg day tolerate addition standard ascites treatment ) 10 cirrhotic subject meet inclusion/exclusion criterion . Subjects monitor change frequency paracentesis , quantity ascites remove , body weight . Additionally , subject laboratory value check frequently first day dose ensure tolerability slow correction/increase serum sodium .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients cirrhosis liver confirm histology and/or combination ultrasound endoscopic examination laboratory evidence Clinically evident ascites treat diet and/or diuretic History 1 therapeutic paracentesis previous 6 month . History variceal bleed Current history Gastrointestinal bleeding within 10 day screen Ascites another cause liver cirrhosis ( i.e . cardiac origin , peritoneal infection , peritoneal carcinoma ) INR ( International normalize ratio ) &gt; 3.0 , neutrophil &lt; 1500 cell/μl , platelet &lt; 40,000/μl serum bilirubin &gt; 3 mg/dl serum sodium &lt; 125 meQ ( milliequivalent ) /L serum potassium &lt; 3.5 meQ/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cirrhotic</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>v2 receptor antagonist</keyword>
</DOC>